Strong growth anticipation may have inflated P/E ratio yet inconsistent recent earnings cast doubt on its sustainability. Current stock prices may not be sustainable as recent trends could affect share price.
A rise in insider selling at Aehr Test Systems signals caution for shareholders. Despite its profitability and growth, the low level of insider ownership raises concerns. Current insider trends suggest it might not be an ideal investment choice.
Pre-Market Stock Movers Gapping up $先鋒自然資源(PXD.US)$soared nearly 10% in premarket trading after The Wall Street Journal reported Pioneer was close to reaching a deal to be bought by Exxon Mobil for about $60 billion. Shares of Exxon were down 3%. $Apellis Pharmaceuticals(APLS.US)$Shares rose 5.5% after Apellis reported growing sales for its Syfovre drug in August. JPMorgan upgraded the stock to ov...
Summary: 1. Aehr Test Systems reported record financial performance in Q4 and fiscal year 2023 with revenue increasing by 28% YoY to $65 million. 2. The company generated a record $10 million in operating cash flow in fiscal 2023, up more than 500% from the prior year, and expects full year total revenue to be at least $100 million in fiscal 2024, representing growth of over 50% YoY. 3. Aehr's strong financial position includes a c...
Aehr Test Systems股票討論區
$AEHR Support / Resistance Levels
Larger Image: tradingview.com...
$Aehr Test Systems(AEHR.US)$
1997年上市,主要做測試系統業務,主要市場在亞洲,當前價格17.88。
5年來營收前3年萎縮,2022年大幅增長2倍,2023年繼續增長27.8%,營業利潤2022年扭虧,2023年增長71%,淨利潤2023年增長54%,
2024上半年營收增長65%,營業利潤增長1.4倍,淨利潤增長1.5倍。
應收和存貨的比例和增速都略快,存貨佔2023年營收的37%,應收佔25.5%。
5年來現金流經營淨額低於投資淨額,還未產生股東盈餘。
目前市盈率36.3,市盈率TTM25.6,可以多觀察幾個季度再判斷。
🚀🚀🚀🚀🚀🚀
📊⚡️📊
專欄Today's Pre-Market Stock Movers and Top Ratings: TSLA, LEVI, PXD, APLS and More
Gapping up
$先鋒自然資源(PXD.US)$ soared nearly 10% in premarket trading after The Wall Street Journal reported Pioneer was close to reaching a deal to be bought by Exxon Mobil for about $60 billion. Shares of Exxon were down 3%.
$Apellis Pharmaceuticals(APLS.US)$ Shares rose 5.5% after Apellis reported growing sales for its Syfovre drug in August. JPMorgan upgraded the stock to ov...
專欄Aehr Test Systems (AEHR) Q4 2023 Earnings Call Transcript Summary
1. Aehr Test Systems reported record financial performance in Q4 and fiscal year 2023 with revenue increasing by 28% YoY to $65 million.
2. The company generated a record $10 million in operating cash flow in fiscal 2023, up more than 500% from the prior year, and expects full year total revenue to be at least $100 million in fiscal 2024, representing growth of over 50% YoY.
3. Aehr's strong financial position includes a c...
暫無評論